Definium’s LSD asset beats analyst expectations in Phase 3 anxiety readout

It’s smooth sailing for Definium Therapeutics as the psychedelic biotech charts another win for its LSD candidate, this time in anxiety. The psychedelic previously notched a late-stage victory in depression.